feed icon

Canadian OK for BioMimetic

Posted on November 4, 2009 at 7:27 am

Canada’s health regulators have given BioMimetic Therapeutics the go-ahead to market its Augment Bone Graft product via an Ontario-based distributor. It’ll be for sale in time for Christmas.

BioMimetic boss sells more shares

Posted on October 26, 2009 at 7:56 am

BioMimetic president and CEO Sam Lynch last week sold 9,000 shares of the company (Ticker: BMTI) as part of a trading plan. He still owns almost 900,000 shares that are worth more than $11 million.

A pop for BioMimetic

Posted on October 6, 2009 at 1:25 pm

Shares of BioMimetic (Ticker: BMTI) are up more than 10 percent at 1:20 p.m. on no apparent news. Volume also isn’t raising any flags, with only about 1.8 times the daily average number of shares having traded hands so far.

UPDATE: OptionMonster’s David Russell has some clues: It appears some investors are betting on good news coming out of a presentation later this week.

Franklin co. ‘overvalued,’ says AFG

Posted on July 8, 2009 at 10:15 am

BioMimetic Therapeutics made a list of “15 Overvalued Small Cap Stocks” as rated by Applied Finance Group.

The 15 firms listed below all meet AFG’s Sell Criteria and all look extremely overvalued according to AFG’s valuation model. These companies all possess the characteristics of a bad investment and may be a potential torpedo lurking in your portfolio. AFG has proven successful since 1996 at identifying good companies as well as sell opportunities, providing a solid buy/sell spread.

BioMimetic puts a bow on its offering

Posted on June 23, 2009 at 10:24 pm

The Franklin-based biotech has raised $17 million from a rights offering. The company (Ticker: BMTI) had enlisted Novo A/S, its largest shareholder, as a backstop but ended up with more demand that it had shares to sell.

BioMimetic does its paperwork

Posted on June 18, 2009 at 8:03 am

The Franklin-based maker of regnerative tissues has submitted several parts of its application to bring Augment Bone Graft to market. Investors are rewarding that by pushing up its shares (Ticker: BMTI) by 7 percent in pre-market action this morning.

BioMimetic extends rights offering

Posted on June 11, 2009 at 4:41 pm

The Franklin-based biotech, which is trying to raise $17 million to give it a cash buffer, has extended the deadline of its rights offering by a week. Over in Denmark, the folks at Novo – who have pledged to backstop the offering – are pulling out their checkbook…

BioMimetic lightens its auction-rate load

Posted on April 15, 2009 at 10:42 pm

In registering papers related to its upcoming $17 million rights offering, the Franklin-based biotech (Ticker: BMTI) says it last week sold $6 million worth of auction-rate securities at full value. The securities had been in limbo since the auction-rate market seized up early last year, stinging many a company, including Nashville-based Louisiana-Pacific.

On a related note, the company has filed an arbitration claim against Deutsche Bank Securities over auction-rate securities it bought on behalf of BioMimetic.

BioMimetic CEO sells block of stock to biggest investor

Posted on January 30, 2009 at 7:12 am

Sam Lynch unloads 50,000 shares in part to cover taxes from exercising options last year. As it has been many times over the past few years, Denmark-based Novo A/S was a willing buyer.

Enough enrollment

Posted on December 11, 2008 at 5:03 pm

BioMimetic Therapeutics (Ticker: BMTI) reaches a milestone in the testing of its new bone graft.

BioMimetic snags key patent

Posted on November 21, 2008 at 9:25 am

The USPTO has granted BioMimetic a patent covering the making of its key regenerative tissues, a landmark CEO Sam Lynch says is one of the “most important accomplishments” in the company’s (Ticker: BMTI) history.

Recent Comments

The Conglomerate